Moderate Evidence
Research Overview
Sulanemadlin Research for Retinoblastoma
An evidence-based overview of research examining Sulanemadlin in the context of retinoblastoma. This page synthesizes findings from peer-reviewed literature.
Research Summary
Advancium Biosciences partnership (2023) developing sulanemadlin for retinoblastoma via intravitreal delivery. Retinoblastoma is a TP53wt tumor type well-suited to dual MDM2/MDMX inhibition mechanism. Pediatric formulation under development.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Sulanemadlin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.